M Gavin

658 total citations · 1 hit paper
10 papers, 458 citations indexed

About

M Gavin is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, M Gavin has authored 10 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Ophthalmology, 4 papers in Radiology, Nuclear Medicine and Imaging and 1 paper in Molecular Biology. Recurrent topics in M Gavin's work include Retinal Diseases and Treatments (5 papers), Ocular Diseases and Behçet’s Syndrome (5 papers) and Retinal Imaging and Analysis (4 papers). M Gavin is often cited by papers focused on Retinal Diseases and Treatments (5 papers), Ocular Diseases and Behçet’s Syndrome (5 papers) and Retinal Imaging and Analysis (4 papers). M Gavin collaborates with scholars based in United Kingdom and United States. M Gavin's co-authors include Richard Gale, Andrew Lotery, Sajjad Mahmood, Sobha Sivaprasad, James Talks, Yit C. Yang, Adnan Tufail, Simon Harding, Faruque Ghanchi and Jonathan Gibson and has published in prestigious journals such as Investigative Ophthalmology & Visual Science, Alimentary Pharmacology & Therapeutics and British Journal of Ophthalmology.

In The Last Decade

M Gavin

10 papers receiving 437 citations

Hit Papers

Defining response to anti-VEGF therapies in neovascular AMD 2015 2026 2018 2022 2015 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Gavin United Kingdom 9 385 275 69 36 35 10 458
Ji Won Lim South Korea 11 445 1.2× 300 1.1× 35 0.5× 31 0.9× 11 0.3× 21 491
Danielle N. Meadows United States 8 214 0.6× 312 1.1× 84 1.2× 23 0.6× 44 1.3× 8 399
Suqin Guo United States 12 287 0.7× 141 0.5× 68 1.0× 41 1.1× 65 1.9× 22 439
Yuying Ji China 10 269 0.7× 131 0.5× 43 0.6× 26 0.7× 16 0.5× 36 334
Sonia Phulke India 3 199 0.5× 98 0.4× 37 0.5× 61 1.7× 24 0.7× 4 268
Marc Figueras‐Roca Spain 14 294 0.8× 201 0.7× 65 0.9× 24 0.7× 25 0.7× 44 400
Samira Khan United States 9 483 1.3× 187 0.7× 70 1.0× 13 0.4× 20 0.6× 10 524
Petri Mäkinen Finland 12 245 0.6× 286 1.0× 65 0.9× 68 1.9× 104 3.0× 31 420
Sharmila S. Boekhoorn Netherlands 9 583 1.5× 437 1.6× 127 1.8× 65 1.8× 62 1.8× 13 665
Laura Wilson United States 4 437 1.1× 336 1.2× 50 0.7× 7 0.2× 22 0.6× 7 461

Countries citing papers authored by M Gavin

Since Specialization
Citations

This map shows the geographic impact of M Gavin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Gavin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Gavin more than expected).

Fields of papers citing papers by M Gavin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Gavin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Gavin. The network helps show where M Gavin may publish in the future.

Co-authorship network of co-authors of M Gavin

This figure shows the co-authorship network connecting the top 25 collaborators of M Gavin. A scholar is included among the top collaborators of M Gavin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Gavin. M Gavin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Amoaku, Winfried M. K., Usha Chakravarthy, Richard Gale, et al.. (2015). Defining response to anti-VEGF therapies in neovascular AMD. Eye. 29(6). 721–731. 262 indexed citations breakdown →
3.
McKibbin, Martin, Richard Gale, M Gavin, et al.. (2015). Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye. 29(S1). S1–S11. 24 indexed citations
4.
Cackett, Peter, et al.. (2013). Intravitreal ranibizumab treatment of wet macular degeneration in SE Scotland - effect on blindness rates and 5 year follow up data. Investigative Ophthalmology & Visual Science. 54(15). 372–372. 5 indexed citations
5.
Acharya, Nisha R., et al.. (2008). Socio-economic deprivation and visual acuity at presentation in exudative age-related macular degeneration. British Journal of Ophthalmology. 93(5). 627–629. 20 indexed citations
6.
Muqit, Mahiul M. K., et al.. (2006). Post‐streptococcal uveitis. Acta Ophthalmologica Scandinavica. 84(3). 424–428. 23 indexed citations
7.
Williams, G.J., et al.. (2006). The prevalence of sight-threatening uveitis in Scotland. British Journal of Ophthalmology. 91(1). 33–36. 33 indexed citations
8.
Williams, Gillian, et al.. (2005). Retinal toxicity during pegylatedα‐interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Alimentary Pharmacology & Therapeutics. 21(6). 723–732. 18 indexed citations
9.
Gavin, M, et al.. (1988). Drug points: Severe toxic erythema caused by diltiazem. BMJ. 296(6628). 1071–1071. 12 indexed citations
10.
Gavin, M, et al.. (1975). The nature of "spots" on soft lenses.. PubMed. 7(3). 345–8, 351. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026